UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 353

Sortiert nach

Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2021-09, Vol.385 (14), p.1280-1291

2021

Volltextzugriff (PDF)

Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma

European urology, 2016-02, Vol.69 (2), p.345-351

2016

Volltextzugriff (PDF)

P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis

The American journal of gastroenterology, 2021-12, Vol.116 (Suppl 1), p.S9-S10

2021

Volltextzugriff (PDF)

P025 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Induction in the Phase 3 True North Study

The American journal of gastroenterology, 2020-12, Vol.115 (Suppl 1), p.S6-S7

2020

Volltextzugriff (PDF)

P030 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Maintenance in the Phase 3 True North Study

The American journal of gastroenterology, 2020-12, Vol.115 (Suppl 1), p.S8-S8

2020

Volltextzugriff (PDF)

P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial

The American journal of gastroenterology, 2021-12, Vol.116 (Suppl 1), p.S9-S9

2021

Volltextzugriff (PDF)

P031 Ozanimod in Patients with Moderate-to-Severe Ulcerative Colitis: Long-Term Safety and Efficacy from the Phase 2 TOUCHSTONE Study 4-Year Open-Label Extension

The American journal of gastroenterology, 2020-12, Vol.115 (Suppl 1), p.S8-S8

2020

Volltextzugriff (PDF)

The prevalence of herbal medicine use among surgical patients in Trinidad

Focus on alternative and complementary therapies, 2011-12, Vol.16 (4), p.266-270

Merritt-Charles, Lorna

2011

Volltextzugriff (PDF)

Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

Intensive care medicine, 2021-02, Vol.47 (2), p.160-169

2021

Volltextzugriff (PDF)

Fr513 INCIDENCE OF INFECTIONS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH OZANIMOD AND RELATIONSHIP TO SIGNIFICANT LYMPHOPENIA: RESULTS FROM A POOLED SAFETY ANALYSIS

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-339-S-340

2021

Volltextzugriff (PDF)

Evaluation of the utilization of the preanaesthetic clinics in a university teaching hospital

BMC health services research, 2006-05, Vol.6 (1), p.59-59, Article 59

2006

Volltextzugriff (PDF)

Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis

Inflammatory bowel diseases, 2024-07

2024

Volltextzugriff (PDF)

950 LONG-TERM SAFETY OF 3 YEARS OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-208-S-208

2023

Volltextzugriff (PDF)

S103 Prevalence of Cardiac Conduction Disorders of Interest Among Adults With Moderately-to-Severely Active Ulcerative Colitis in the US: A Real-World Analysis

The American journal of gastroenterology, 2022-12, Vol.117 (12S), p.S27-S27

2022

Volltextzugriff (PDF)

Su1771 SAFETY OF LONG-TERM OZANIMOD TREATMENT FOR UP TO 4 YEARS BY AGE GROUP IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-805-S-806

2024

Volltextzugriff (PDF)

S6 Pregnancy Outcomes in Patients With Ulcerative Colitis, Crohn’s Disease, and Relapsing Multiple Sclerosis: Results From the Ozanimod Clinical Development Program

The American journal of gastroenterology, 2023-12, Vol.118 (12S), p.S2-S3

2023

Volltextzugriff (PDF)

S1161 Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn’s Disease, and Relapsing Multiple Sclerosis

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S888-S888

2023

Volltextzugriff (PDF)

Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study

Journal of Crohn's and colitis, 2021-07, Vol.15 (7), p.1120-1129

2021

Volltextzugriff (PDF)

Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn's Disease, and Relapsing Multiple Sclerosis

Inflammatory bowel diseases, 2024-01

2024

Volltextzugriff (PDF)

128 SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS OVER TIME: POOLED ANALYSIS FROM PHASE 2, PHASE 3, AND OPEN-LABEL EXTENSION TRIALS

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-35-S-35

2021

Volltextzugriff (PDF)

Performance of a pediatric ambulatory anesthesia program - a developing country experience

Pediatric anesthesia, 2006-04, Vol.16 (4), p.388-393

2006

Volltextzugriff (PDF)

S812 Hepatic Safety of Ozanimod in Ulcerative Colitis and Relapsing Multiple Sclerosis Phase 3 Trials

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e581-e581

2022

Volltextzugriff (PDF)

Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses

Clinical gastroenterology and hepatology, 2024-05, Vol.22 (5), p.1067-1076.e3

2024

Volltextzugriff (PDF)

Tu1458: LONG-TERM USE OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-969-S-970

2022

Volltextzugriff (PDF)

15: LONG-TERM CARDIAC SAFETY OF OZANIMOD IN PHASE 3 CLINICAL PROGRAM OF ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-5-S-6

2022

Volltextzugriff (PDF)

1 – 25 von 353

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(319)
Mit Volltextzugriff
(315)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma

P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis

P025 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Induction in the Phase 3 True North Study

P030 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Maintenance in the Phase 3 True North Study

P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial

P031 Ozanimod in Patients with Moderate-to-Severe Ulcerative Colitis: Long-Term Safety and Efficacy from the Phase 2 TOUCHSTONE Study 4-Year Open-Label Extension

The prevalence of herbal medicine use among surgical patients in Trinidad

Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

Fr513 INCIDENCE OF INFECTIONS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH OZANIMOD AND RELATIONSHIP TO SIGNIFICANT LYMPHOPENIA: RESULTS FROM A POOLED SAFETY ANALYSIS

Evaluation of the utilization of the preanaesthetic clinics in a university teaching hospital

Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis

950 LONG-TERM SAFETY OF 3 YEARS OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION

S103 Prevalence of Cardiac Conduction Disorders of Interest Among Adults With Moderately-to-Severely Active Ulcerative Colitis in the US: A Real-World Analysis

Su1771 SAFETY OF LONG-TERM OZANIMOD TREATMENT FOR UP TO 4 YEARS BY AGE GROUP IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION

S6 Pregnancy Outcomes in Patients With Ulcerative Colitis, Crohn’s Disease, and Relapsing Multiple Sclerosis: Results From the Ozanimod Clinical Development Program

S1161 Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn’s Disease, and Relapsing Multiple Sclerosis

Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study

Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn's Disease, and Relapsing Multiple Sclerosis

128 SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS OVER TIME: POOLED ANALYSIS FROM PHASE 2, PHASE 3, AND OPEN-LABEL EXTENSION TRIALS

Performance of a pediatric ambulatory anesthesia program - a developing country experience

S812 Hepatic Safety of Ozanimod in Ulcerative Colitis and Relapsing Multiple Sclerosis Phase 3 Trials

Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses

Tu1458: LONG-TERM USE OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

15: LONG-TERM CARDIAC SAFETY OF OZANIMOD IN PHASE 3 CLINICAL PROGRAM OF ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS

Suchergebnisse filtern